BioSpace News Archive

Microbot Medical Inc. announced the system has surpassed its 100th catheterization during multiple pre-clinical studies, with a 95% success rate of reaching pre-determined vascular targets, such as distal branches of hepatic, gastric, splenic, mesenteric, renal, hypogastric arteries.

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2023, after U.S. markets close on Thursday, May 18, 2023.

BioSig Technologies, Inc. announced that it will be presenting data at Heart Rhythm 2023, the Heart Rhythm Society’s 44th annual meeting, on May 19-21, 2023, in New Orleans, Louisiana.

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTCQB: SRBCF) (“Sirona”) is excited to announce that Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer, will be presenting the Company’s latest anti-aging technology, TFC-1326, at the upcoming BIO International 2023 conference in Boston.

QuVa Pharma, Inc. announced that it is expanding its product label platform by adding 2D barcodes on all products, adhering to GS1 standards.

Smartlens, Inc., a clinical-stage ophthalmic technology company, has announced positive clinical results for miLens, a non-invasive, electronics-free, soft contact lens for monitoring intraocular pressure (IOP).

Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) announced today details for the release of its results for the quarter ended March 31, 2023.

Varex Imaging Corporation (Nasdaq: VREX) announced today the launch of its XRD 3131N digital X-ray detector, addressing the growing need for faster and more comprehensive inspection in high-paced Electric Vehicle (EV) battery manufacturing, strengthening our current portfolio for the EV battery inspection market.

Agenus announced a data update on botensilimab in combination with balstilimab for patients with non-microsatellite instability-high metastatic colorectal cancer has been selected for a late-breaking oral presentation at the upcoming ESMO World Congress on Gastrointestinal Cancer, to be held June 28 – July 1, 2023 in Barcelona, Spain.

Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) today announced that its pre-clinical manuscript entitled “Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (GLP-2), Teduglutide - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome” has been accepted for publication by the International Journal of Peptide Research and Therapeutics.